Fecal miRNA Biomarker Detection for Colorectal Cancer Screening

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current non-invasive screening methods for colorectal cancer have limited sensitivity and specificity, and existing biomarkers are not effective in detecting colorectal neoplasia at an early stage, leading to late-stage diagnoses and high mortality rates.

Innovation Solution

The use of fecal miRNAs as novel biomarkers, where miRNAs are extracted and amplified directly from stool specimens using a modified protocol, allowing for the detection of unique expression patterns associated with colorectal neoplasia, enabling a non-invasive and reliable screening method.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If fecal glycoproteins are extracted and reacted with antibodies for colon cancer screening, then the detection method is non-invasive, but the sensitivity and specificity are limited

Engineering Contradiction:

Improvenon-invasive screeningVSAvoiddetection sensitivity and specificity

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent changes the biomarker parameter from fecal glycoproteins to fecal miRNAs, which are more stable and exhibit higher expression differences in cancer patients. This parameter change enables both non-invasive screening and improved detection sensitivity/specificity simultaneously

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses miRNA expression patterns as a molecular copy or signature of colorectal neoplasia, detecting the disease state through characteristic miRNA profiles in fecal samples rather than direct tissue examination

Inventive Principle:

Principle #26Copying

2Ease of operation

If existing biomarkers are used for early stage detection, then the screening is non-invasive, but the detection accuracy is insufficient leading to late-stage diagnoses

Engineering Contradiction:

Improvescreening accessibilityVSAvoidearly stage detection accuracy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent replaces traditional mechanical/biochemical detection methods (antibody-antigen reactions with glycoproteins) with molecular biology-based detection of miRNA expression patterns, which provide higher accuracy for early cancer detection while maintaining non-invasive fecal sampling

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Measurement precision

If miRNAs are extracted and amplified directly from stool specimens using modified protocol, then the detection sensitivity is improved, but the procedure complexity increases

Engineering Contradiction:

ImprovemiRNA detection sensitivityVSAvoidextraction and amplification procedure

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the complex miRNA detection process into distinct modules: RNA extraction from fecal samples, reverse transcription to cDNA, and quantitative PCR amplification. This segmentation allows each step to be optimized independently and facilitates standardization

Inventive Principle:

Principle #1Segmentation

4Reliability

If fecal miRNAs are used as biomarkers, then the reproducibility is high, but the method requires modified extraction protocols

Engineering Contradiction:

ImprovereproducibilityVSAvoidprotocol standardization

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent establishes specific parameter ranges for miRNA extraction (RNA concentration thresholds, extraction buffer compositions, incubation temperatures and times) that ensure reproducible results across different laboratories while maintaining ease of implementation

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a highly reproducible and sensitive method for detecting colorectal neoplasia, with elevated levels of miR-21 and miR-106a in stool samples indicating the presence of adenomas and CRCs, potentially reducing mortality by enabling early detection.

Implementation Method 1

amplifying the transcribed cDNA using a polymerase chain reaction assay to obtain the one or more amplified miRNA

Methodology Applied

Scientific EffectPolymerase chain reaction:

Implementation Method 2

measuring a total RNA/miRNA concentration in the supernatant using a spectrophotometer

Methodology Applied

Scientific EffectSpectrophotometry: Absorption Spectroscopy

Implementation Method 3

centrifuging the suspension, separating a supernatant from the centrifuged suspension

Methodology Applied

Scientific EffectCentrifugation: Centrifugal Separation

Data Source

PatentUS8956817B2Identification of microRNAs (miRNAs) in fecal samples as biomarkers for gastroenterological cancers

Publication Date: 2015.02.17 BAYLOR RESEARCH INSTITUTE

AI summary

A simple, rapid, inexpensive, and promising commercial biomarker assay method for multiple diseases is described herein. The present invention detects miRNA-based biomarkers in human stool specimens. The method of the present invention amplifies miRNA directly from stool specimens without any prior miRNA extraction. Differential expression of specific microRNAs in stool of colorectal cancer CRC and adenoma patients suggest fecal microRNAs as a novel potential biomarker for colorectal neoplasia detection. The method of the present invention has diagnostic, prognostic, and therapeutic relevance for gastroenterological cancers/colorectal cancer and as well as further acquired or hereditary GI diseases.